CA2046337C

CA2046337C - Improved transdermal system for the administration of pharmacological compounds under ph-controlled conditions

Info

Publication number: CA2046337C
Application number: CA002046337A
Authority: CA
Inventors: Arun Rajaram Gupte; Uwe Rohr; Bernd Zierenberg
Original assignee: Boehringer Ingelheim International GmbH
Current assignee: Boehringer Ingelheim International GmbH
Priority date: 1989-12-01
Filing date: 1990-11-29
Publication date: 2004-05-25
Anticipated expiration: 2010-11-29
Also published as: FI913645A0; RU1834665C; EP0456792B1; JPH04506811A; HU912638D0; PT96045B; HUT59615A; KR0143549B1; DE59010885D1; ATE185492T1; DE3939703C2; KR920700704A; NO912985D0; AU637861B2; FI107707B; NO302156B1; ZA909624B; WO1991007998A1; AU6875791A; CA2046337A1

Abstract

The invention relates to an improved transdermal administration of pharmacologically active compounds.

Description

x 56177J.20 The invention relates to an improved transdermal system in the form of a plaster for the administration of pharmacologically active substances under skin surface-pH-controlled conditions.
The transdermal administration of pharmacologically active compounds using transdermally therapeutic systems has been known in the prior art for some time. Suitable plasters for this purpose are disclosed for example in US
Patent 3558122 and 3558123. Although in these and numerous subsequent patent applications a number of active substances are shown to be suitable, it has been found in practice that unexpected problems may occur when .
they are used on patients even if tests carried out in vitro have already demoa~strated that the plaster containing the active substance will release the active substance in sufficient quantities.
However, when the theory was put into practice on humans, the sufficiently high or constant blood level values expected could not be achieved. Thus, for example, clenbuterol is used orally in the form of tablets or syrups as a Q-sympathomimetic for treating bronchial asthma. Contrary to expectation, the transdermal administration of clenbuterol has not hitherto resulted in constant blood level values.
It has been found, surprisingly, that the flux rate for the active substance in the transdermal administration of clenbuterol can be crucially improved if the pH of the skin surface is maintained at a constant level between 6.0 and 8.5.
The flux rate of an active substance through the skin is defined as the quantity of active substance per unit of area of the skin and per unit of time and is normally given in [ug/cmz.h]. The flux rate for clenbuterol,reaches a maximum in the pH range specified above, but decreases sharply at higher and lower gH
levels.

The pH level of the skin surface differs between individual people and at different times. A pH level of 5.5 to 6.0, taken as standard, will fluctuate in individual cases between pH 4.5 and 8.0 and will depend on a number of different ~~ factors. Fluctuations :in the pH level may be caused on the one hand by the plaster itself and on the other hand by the active substance. As can be seen from Fig. I the flux rate of clenbuterol is reduced drastically outside the pH range specified, with the result that it is no longer guaranteed that the skin will be sufficiently permeable for clenbuterol.
The invention further relates to transdermal systems which make it possible 1.o achieve a constant pH level on the skin and thus allow active substances to diffuse through the skin in the range of their maximum flux rate. According to the invention, this establishes the optimum flux rate for the active substance in patients, irrespective of the inherent pH
of the skin.
Such systems may be constructed by having, on the side which comes into contact with the skin, a chemical substance (additive) which buffers the pH value on the surface of the skin in the desi:red area. Obviously, the substances or mixtures of substances :involved must be pharmacologically acceptable. For achieving a predetermined pH value on the skin, it is appropriate to use additives such as, for example, weak bases, weak acids, organic and inorganic salts which form a buffer system with the skin surface, or buffer mixtures (buffer systems).
The invention provides a transdermal therapeutic delivery system comprising a plaster having a backing layer impervious to therapeutically active substance, a reservoir of -2a-active substance situated or adapted to be situated between the backing layer and the skin and means for securing the plaster on the skin, and in which at least one pharmacologically acceptable additive cap<~ble of adjusting the pH of the skin ~~ surface to a desired predeterminable value is present.
The invention also provides the use of at least one pharmacologically accepi~able additive in a transdermal therapeutic delivery system comprising a plaster having a backing layer impervious to therapeutically active substance, a reservoir of active substance situated or adapted to be situated between the backing layer and the skin and means for securing the plaster on the skin, and optionally, a membrane for controlling the relE:ase of active substance, for adjusting the pH of the skin surf<~ce within a range which corresponds to the maximum flow rate [E.~g/cm2h] of said active substance.
The invention further provides the use of a transdermal therapeutic delivery system comprising a plaster having a backing layer .impervious to therapeutically active substance, a reservoir of active substance situated or adapted to be situated between i:he backing layer and the skin and means for securing the plaster on the skin, and in which at least one pharmacologically acceptable additive capable of adjusting the pH of the skin surface 1.o a desired predeterminable value is present, for delivering a pharmacologically active substance.
The invention further provides a method for the preparation of a transdE:rmal therapeutic delivery system which comprises bringing into admixture in solution in an organic solvent, a therapeutically active substance, a pharmacologically acceptable additive capable of adjusting the pH of the skin surface t:o a desired predeterminable level and a polymer, evaporating the. solvent to form a polymer film containing said substance, and said additive, said film being -2b-adapted to be provided with or used in conjunction with a water-vapour-impervious backing layer and optionally a skin securing layer.
The quantity of additives should not be too small, so as to ensure that the pH value on the surface of the skin can be adjusted to the desired level for the entire period of time that the plaster is worn.
The quantity of additive is generally between 2 and 10% by weight, based on the weight of the active substance 1C reservoir of the transdE:rmal system, whilst a range between 4 and 6% by weight is pre:Eerred.

r This quantity of additive is sufficient to adjust the pH of the skin to a predetermined level for a period of 1 to 7 days.
The advantages of such an adjustment of the pH value are, on the one hand, that basic active substances which set up a basic pH level on the skins surface are able to shift the pH of the skin into the acid range by the addition of acid salts. In this way, the acceptability of transdermal systems can be improved substantially, since the growth of bacteria in the acid pH range is substantially reduced.
Another advantage of adjusting the pH on the surface of the skin is the fact that slightly acidic or basic active substances will form a buffer system by the addition of suitable salts and a defined pH will be obtained, so that fluctuations in the pH of the skin surface can be balanced out.
Suitable salts or weak acids which are suitable as additives for adjusting the pH include the following for example:
Disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium acetate, potassium dihydrogen phosphate, sodium carbonate, sodium hydrogen carbonate; boric acid, sodium borate, citric acid, sodium or potassium citrate, monocalcium orthophosphate (Ca(HzP04)Z), potassium hydrogen phosphate, dipotassium hydrogen phosphate, tartaric acid, potassium or sodium tartrate, sodium hydrogen phthalate.
Buffer systems and buffer mixtures with which a pH
value of between 3 and 10 can be achieved are sufficiently well known from the prior art.
The following are examples of active substances the diffusion characteristics of which can be changed by adjusting the pH:
Physostigmine, clonidine, fentanyl, MR 2264 (N-(2-methoxyethyl)-noroxy-morphone), ephedrine, nicotinic-acidamide, clenbuterol, pramipexol, lisuride, 1 !' n ,~ iJ
il °.~
_ 4 .
terbutaline, salbutamol, hexoprenaline, insulin, vasopressin, atrial natriuretic peptide (ANP).
The advantages and findings according to the invention can also be applied to other active substances occurring in the form of weak basis or weak acids.
The plaster according to the invention may also advantageously be used to make the pH of the skin surface slightly acidic (pH = 5.5 to 6.9), so as to avoid undesirable bacterial growth and possible skin irritations resulting from it.
Neutral molecules the flux rate of which is unaffected or only slightly affected by the pH of the skin are particularly suitable for this purpose e.g.
nitroglycerine.
Transdermal systems suitable for use according to the invention for adjustment of the pH value are known from the prior art. Generally, they are matrix systems of one of the polymers or copolymers listed below.
Polymethacrylate, polyvinylpyrrolidone, ethylzellulose, hydroxypropylmethylzellulosephthalate, polyvinylalcohol or copolymers thereof with vinyl laurate or maleic acid, vinyl acetate or copolymers thereof with vinyllaurate, or malefic acid, vinyl acetate or copolymers thereof with vinyl laurate or malefic acid, polyvinylether, butyl rubber and polycaprolactam.
Preferred, polymers and copolymers are those produced by emulsion polymerisation. With polymers of this kind, it is known that the release of active substance can be adjusted by varying the particle size of the polymer particles, by varying the layer thickness in the range between 40 and 200 hem, preferably up to 140 Vim, and by varying the glass transition temperature.
The particle size relates to the particle diameter of the polymeric material after it has been produced and may be up to 500 ~Cm. The particle size (diameter) can be adjusted depending on the conditions of polymerisation.
A reduction in the particle size results in an increase in the rate of release.

The glass transition temperature can be adjusted by changing the monomer composition and is, for example, between -20° and +80°C, preferably between -20° and +
40'C, particularly preferably between -10' and +30°C. An increase in the glass transition temperature is connected with a lowering of the rate of release.
Using the emulsion polymerisation method, the following polymers may be prepared, for example PVC, polylactides, polystyrene, polyvinylacetate,.
polybutadiene, polyacrylnitrile, polyvinylester, polyvinylether and copolymers thereof. Emulsion polymerised copalymers of methyl and/or ethyl esters of acrylic and methacrylic acid are preferred. The molecular weight of the emulsion polymers should be between 10~ and 10~. The carrier material may be recovered as a solid, e.g. by freeze drying, with the particles of polymer retaining their shape and size.
Matrix systems for transdermal administration consist of a backing layer which contains the active substance, a reservoir containing the active substance (active substance matrix store) and means for securing it to the skin.
The release of active substance is controlled either by a suitable choice of the polymer matrix - as disclosed for example in European Patent 86997 - or by means of suitable membranes, as described for example in US
Patents 3598122 and 3598123.
In one embodiment, the system according to the invention contains a backing layer which is impervious to the active substance, a polymer matrix containing the active substance, with 2 to 10% of a weak base, a weak acid or a salt for adjusting the pH of the skin and means for securing the system to the skin.
The matrix which contains the active substance preferably consists of an emulsion-polymerised polyacrylate. Systems of this kind are disclosed for example in published German Application 2920500, European 6 _ Patent Application 209121 and European Patent 86997, the contents of which are hereby referred to.
Particularly preferred emulsion polymers are the copolymers based on the alkyl esters of acrylic and methacrylic acid. The general formula is ( CHZ-CRS-CHZ-CRS ] ~
COORZ COORS
wherein Ry = H, CH3 and RZ = H, C~-C4-alkyl C~-C4-alkyl-N ( C~-C4-alkyl ) 2.
The average molecular weight is between 6.104 and 1.6 - 10T, the range between 104 and 106 being preferred.
The following Eudragit emulsion polymers E 30 D MW 800 000 R1 = H, CH3, . Rz = CH3CzHs' E 12,5/100 MW 150 000 R~ = CH3 RZ = CHZ-CHz-N ( CH3 ) z CH3 , C4H9 .
L/S 100 MW 135 000 R~ = CH3 ~ RZ = H , CH3 made by Rohm GmbH of Darmstadt and mixtures thereof are preferred.
In order to produce the embodiment described above having a matrix of an emulsion polymer, the following procedure is used:
The freeze dried latex is taken up in an organic solvent or mixture of solvents which is capable of dissolving both the drug and the polyacrylate. The additive for adjusting the pH on the skin is either added in finely divided form as a powder or, if the solvent is water-miscible, in the form of a solution or suspension in water. Examples of solvents include lower aliphatic alcohols, ethers, ketones, esters, hydrocarbons or halohydrocarbons, particularly those having a boiling point below 100'C which evaporate easily. Mixtures of solvents may also be used. The viscosities of the starting solution can be varied by a suitable choice of solvent or solvent mixture. The films should normally have a thickness of about 50 to 200 um. The temperature at which the solution dries to a film is normally from ambient temperature to, at most, the boiling temperature of the solvent or the solvent mixture used, although normally drying will be carried out at lowest possible temperatures owing to the instability of many pharmaceutically active substances and the risk of bubbl.s formation in the film. The film may be produced or discontinuously. The films obtained are cut into suitable pieces or stamped out and packaged in the usual way for the production of transdermal preparations, possibly by applying a supporting and/or covering layer to one side of the film which contains the active substance and by attaching an adhesive layer with a removable protective coating to the other side. It may be attached to the skin using an adhesive covering plaster.
In another embodiment in which the transdermal system contains a membrane for controlling the release of active substance, the additives for adjusting the pH are provided on or in the side of the membrane facing the skin.
In another embodiment, the transdermal system takes the form of a multi-chamber system, with one or more active substances incorporated in separate chambers whilst according to the invention the additives for adjusting the pH are provided in other chambers. The additives may occur in discrete chambers, e.g. in the form of a gel, solution or suspension.
Irrespective of the nature of the matrix system, the additive for adjusting the pH may be contained in a separate layer on the side which is next to the skin.
This layer may take the form of a tackypolymer, a non-tackypolymer, a gel, e.g. an agarose gel, in the form of a (viscous) solution or in the form of small particles.
Tt is not absolutely necessary for the separate layer _8_ containing the additive to cover the entire active substance matrix.
The present invention alsoo relates to a transdermal system, free from active substance, in the form of a plaster for adjusting the pH on the skin surface, characterised in that the plaster contains recesses, These plasters may be used as under-plasters for placing under any plaster which contains active substance, e.g.
in order to improve the optimum flux rate of existing systems. In this case, the active substance is chiefly diffused through the surface of the skin which is not covered by the under-plaster.
In another embodiment of an under-plaster according to the invention containing no active substance, this may also be constructed so as to cover the skin completely, provided that neither its thickness nor its composition cause it to interfere with the diffusion of the active substance from the plaster containing the active substance. This is the case, for example, with thin polyacrylate films.
The composition of the under-plaster according to the invention with regard to the polymer (matrix) and the additive for adjusting the pH is analogous to that of the systems containing active substances described hereinbefore.
In another embodiment, the transdermal system contains, on the side facing the skin, small needles which pass through the stratum corneum and thus allow drugs to diffuse, unobstructed, through the pin pricks.
(The "mosquito" system). The salts required keep the active substances in solution, on the one hand, so that they can penetrate through the stratum corneum into the epidermis without crystallising out, but by a suitable choice of pH, in the acid buffered range, also prevent the growth of bacteria, so as to avoid the use~of preservatives on the skin which may cause reactions of intolerance. Plasters of this type for transdermal use are described for example in DE-OS 2305989.

20~~a~~~d Fig. 9 shows the permeability P of clenbuterol through human skin (function A); P is given in [cm/sec].
Curve H illustrates the water solubility of the substance depending on the pH value [mg/ml]. Curve C shows the flux rate of clenbuterol over a wider pH range. (The right-hand ordinate in Fig. 9 is shown logarithmically).
Description of the Figures Fig. 1 of the drawings shows a plan view of a plaster 1 according to the invention. By contrast to what is shown in the drawing, the plaster may just as easily be rectangular or circular.
Fig. 2 shows the cross section of a preferred embodiment of the plaster 10, in which the active substance 21 and the additive 22 for adjusting the pH are uniformly distributed in a polymer matrix. The protective film 30 is removed before use so as to expose the adhesive surface 31.
Fig. 3 shows another embodiment of the plaster 10, in which the release of active substance is controlled by a membrane 33. The additive 22 is contained in a separate layer 34. This drawing does not show the protective film 30.

Fig. 4 shows a similar embodiment of the plaster 10, but with the layer 34 consisting of a tackypolymer which contains the additive 22.
Fig. 5 shows a cross section through a plaster which has on its underside small needles for penetrating the topmost layer of skin. The polymer matrix 20 contains the active substance 21 and the additive 22. The flattened outer sides 35 of the plaster contain, on the underside, an adhesive layer 31 for fixing to the skin.
The examples which follow are intended to illustrate the invention.
Preparation Example 1 Preparation of clenbuterol-eudragit NE 30 D
scilution:
Acetone 1734 mg is placed in a heatable container with an airtight seal, with stirring, and Clenbuterol 21 mg and Citric acid 21 mg are slowly added thereto, with stirring.
Eudragit NE 30 D 434 mg is added.
The heater is closed and heated to 40'C with stirring. At this temperature, stirring is continued until a homogeneous solution has formed. The solution must be free from clusts. The viscosity of the solution should be between 3000 and 4000 mPas. The heated solution is applied by means of a direct coating apparatus consisting of applicator means, heating channel and cooling means. A fixed blade (doctor blade) is arranged at right angles to the direction of advance in the applicator means.
In front of the blade, the viscous acetone solution prepared as described above is applied to a carrier film.
The film is thus produced by a method as described in "Technologische ~chriftenreihe: Veredelung 204~~~~

bahnformiger Materialien, Besc:hichten and Impragnieren,"
Berger Verlag, Frankfurt.
The acetone in the cast film is evaporated either by the ambient temperature or by means of a heating channel.
The coated carrier strip is cooled and then wound onto a film. Pieces of any desired size may be stamped out.
The pieces are stuck into a covering plaster and can then be stuck onto the patient.
Preparation Example 2 Preparation of the clenbuterol-Eudragit NE 30 D
solution:
Acetone 1734 mg is placed in a heatable container, with an airtight seal, with stirring and Clenbuterol 21 mg and Sodium carbonate 21 mg are slowly added thereto with stirring.
Eudragit NE 30 D 434 mg is added.
Processing is continued as described in Preparation Example 1, except that a suspension is formed instead of a clear solution.
Permeability of pH-modified clenbuterol CPA through human skin:
Composition of the CPAos:
pH 10.0 pH 3.5 Clenbuterol 5 % 5 %
Citric acid 5 %
Na2C03 5 %
Polymethacrylate 90 % 90 %
Eudragit' E 30 D

2~~~' A Franz cell was used as the release apparatus.
This is a conventional method of testing the release of drugs from pharmaceutical formulations. Samples were taken after 24 hours and 48 hours and the clenbuterol content was determined.
pH-value 3.5 pH-value 10.0 Cell 1 2 3 1 2 3 Clenbuterol 3.48 0.65 2.64 7.8 11.44 9.84 Diffusion after 24 hours in ~g/cmz Clenbuterol 5.52 1.69 6.04 21.7 27.3 24.2 Diffusion after 48 hours in ~g/cmz It is clear that a higher diffusion rate is found at an alkaline pH than at an acid pH.
Example 2 Fig. 6 shows results regarding the pH of the skin surface determined underneath the system on the skin after 5 days' wearing, using a surface pH electrode. The systems tested differ in their concentration of citric acid in the polymethacrylate matrix. It is clear that only a citric acid concentration of more than 1~ can bring about any significant change in the surface pH of the skin. The words "values 1, 2 and 3" in Fig. 7 refer to test subjects.
Example 3 Fig. 7 shows surface pH levels of drug-containing CPA's of basic active substances which were changed by 2~~~3~'~

the addition of 5% citric acic! or NaZCO3. As a comparison, the surface pH found without the addition of salts or ionic substances was also determined. It is clearly apparent that the pH can be varied both to basic pH levels and to acid pH levels.
Exampjle 4 Fig. 8 shows the pH on the skin under a transdermal therapeutic system applied thereto and worn for 6 days.
The pH adjustments on the surface are clearly shown. The pH value selected is maintained on the skin for this period.

Claims

CLAIMS:

1. A transdermal therapeutic delivery system comprising a plaster having a backing layer impervious to therapeutically active substance, a reservoir of active substance situated or adapted to be situated between the backing layer and the skin and means for securing the plaster on the skin, and in which at least one pharmacologically acceptable additive for adjusting the pH
of the skin surface within a range which corresponds to the maximum flow rate [µ.g/cm 2] of the active substance through the skin is present.

2. The delivery system according to claim 1, further comprising a membrane for controlling release of the active substance from the reservoir to the skin.

3. The delivery system according to claim 1 or. 2, in which the pharmacologically acceptable additive comprises a weak base, a weak acid, one or more inorganic or organic salts which form a buffer system with the skin surface, or a buffer system, or mixtures thereof, capable of providing a pH of from 3 to 10.

4. The delivery system according to any one of claims 1 to 3, in which the active substance and additive are provided in a polymer matrix.

5. The delivery system according to claim 4, wherein the polymer matrix is formed from an emulsion-polymerised polyacrylate.

6. The delivery system according to claim 4 or 5, wherein the additive is present in an amount of from 2 to 10% by weight based on weight of active ingredient-containing polymer matrix.

7. The delivery system according to any one of claims 1 to 6, wherein the active substance is selected from the group consisting of physostigmine, clonidine, fentanyl, MR
2264 (N-(2-methoxyethyl)-noroxy-morphone), ephedrine, nicotinicacidamide, clenbuterol, pramipexol, lisuride, terbutaline, salbutamol, hexoprenaline, insulin, vasopressin and atrial natriuretic peptide (ANP).

8. The delivery system according to claim 7, wherein the active substance is clenbuterol.

9. The delivery system according to any one of claims 1 to 8, wherein said at least one pharmacologically acceptable additive is capable of adjusting the pH of them skin surface to a value of from 6.0 to 8.

10. The delivery system according to any one of claims 1 to 8, wherein said at least one pharmacologically acceptable additive is capable of adjusting the pH of the skin surface to a value of from 5.5 to 6.9.

11. Use of at least one pharmacologically acceptable additive in a transdermal therapeutic delivery system comprising a plaster having a backing layer impervious to therapeutically active substance, a reservoir comprising an active substance situated or adapted to be situated between the backing layer and the skin and means for securing the plaster on the skin, for adjusting the pH of the skin surface within a range which corresponds to the maximum flow rate [µg/cm 2] of the said active substance through the skin.

12. The use according to claim 11, wherein the transdermal therapeutic delivery system further comprises a membrane for controlling release of the active substance from the reservoir to the skin.

13. The use according to claim 11 or 12, wherein said pharmacologically acceptable additive for adjusting the pH
of the skin surface is a weak base, a weak acid, one or more organic or inorganic salts which form a buffering system, or mixtures thereof, capable of providing a pH of 3 to l0.

14. The use according to any one of claims 11 to 13, wherein the active substance and additive are provided in a polymer matrix.

15. The use according to claim 14, wherein the polymer matrix is formed from an emulsion-polymerized polyacrylate.

16. The use according to claim 14 or 15, wherein the additive is present in an amount of from 2 to 10% by weight based on weight of active ingredient-containing polymer matrix.

17. The use according to any one of claims 11 to 16, wherein the active substance is selected from the group consisting of physostigmine, clonidine, fentanyl, MR 2264 (N-(2-methoxyethyl)-noroxy-morphone), ephedrine, nicotinicacidamide, clenbuterol, pramipexol, lisuride, terbutaline, salbutamol, hexoprenaline, insulin, vasopressin and atrial natriuretic peptide (ANP).

18. The use according to claim 17, wherein the active substance is clenbuterol.

19. The use according to claim 17 or 18, wherein the pH is maintained at between 6.0 and 8.5.